Last update 24 Mar 2025

Xirestomig

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Dual PD-L1 checkpoint inhibitor/4-1BB costimulator (Antengene), PD-L1/4-1BB bi-specific antibody (Antengene), ATG 101
+ [4]
Action
agonists, inhibitors, stimulants
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Hodgkin LymphomaPhase 1
China
08 Jul 2022
Solid tumorPhase 1
China
08 Jul 2022
Hematologic NeoplasmsPhase 1
China
22 Jun 2022
Advanced Malignant Solid NeoplasmPhase 1
United States
15 Dec 2021
Advanced Malignant Solid NeoplasmPhase 1
Australia
15 Dec 2021
Mature B-Cell NeoplasmPhase 1
United States
15 Dec 2021
Mature B-Cell NeoplasmPhase 1
Australia
15 Dec 2021
Metastatic Solid TumorPhase 1
United States
15 Dec 2021
Metastatic Solid TumorPhase 1
Australia
15 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
wtksytsady(diaydnyjlu) = ldycqmrwoh rcqtqjjhny (anlgrqrhlc )
Positive
07 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free